KalVista Pharmaceuticals (KALV) Stock Statistics & Valuation Metrics

KalVista Pharmaceuticals has a market cap or net worth of $1.37B. The enterprise value is $1.42B.

KalVista Pharmaceuticals has 51,222,490 shares outstanding. The number of shares has decreased by -2.65% in one year.

KalVista Pharmaceuticals’s return on equity (ROE) is 60.60 and return on invested capital (ROIC) is -58.89%.

The current PE Ratio of KalVista Pharmaceuticals is ―. KalVista Pharmaceuticals’s PEG ratio is 0.40.

In the last 12 months, KalVista Pharmaceuticals had revenue of 73.62M and earned -164.29M in profits. Earnings per share was -3.23.

In the last 12 months, operating cash flow was -114.86M and capital expenditures 65.00K, giving a free cash flow of -114.80M billion.

KalVista Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

KalVista Pharmaceuticals upcoming earnings date is Jul 2, 2026, Before Open (Confirmed).

KalVista Pharmaceuticals as a current ratio of 5.58, with Debt / Equity ratio of -10483.47%

In the past 12 months, KalVista Pharmaceuticals has paid -7.13M in taxes.

KalVista Pharmaceuticals EV to EBITDA ratio is -4.37, with an EV/FCF ratio of -8.93.

KalVista Pharmaceuticals has $300.21M in cash and marketable securities with $284.21M in debt, giving a net cash position of $16.01M billion.

Gross margin is 68.70%, with operating margin of -233.42%, and net profit margin of -223.16%.

The average price target for KalVista Pharmaceuticals is $31.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy